In a randomized, double-blind, placebo-controlled crossover study of 67 patients with peripheral neuropathic pain, bupropion lowered mean daily pain from 6.4 to 5.5, with an average benefit vs. placebo of -0.5 (95% CI -0.8 to -0.1; p=0.005). The study found this modest effect was independent of conditioned pain modulation and sensory phenotype, positioning bupropion as a potential backup option when first-line treatments fall short.

Why It Matters To Your Practice

• NPs and PAs are often the clinicians who hear first that neuropathic pain meds are not working or are causing intolerable side effects.

• This trial suggests bupropion may be a practical alternative for patients with peripheral neuropathic pain who cannot tolerate or do not respond to standard first-line agents.

• The benefit did not depend on conditioned pain modulation status or sensory phenotype, so you do not need specialized phenotyping to recognize possible candidates.

Clinical Benefits

• Mean daily pain improved by 0.9 points overall, from 6.4 to 5.5 during bupropion treatment.

• Compared with placebo, the average treatment effect was -0.5 points, which was statistically significant.

• Ten patients achieved at least 30% pain reduction, and six achieved at least 50% pain reduction.

• Bupropion was well tolerated, which may matter when balancing analgesia with real-world adherence.

Managing Risks

• The effect size was modest, and there was no significant improvement on the pain relief scale.

• The number needed to treat for 50% pain reduction was 15, higher than what is typically reported for first-line neuropathic pain therapies.

• This supports setting expectations early: bupropion is not a first-choice replacement, but a reasonable option when standard therapies are ineffective or poorly tolerated.

• Larger studies are still needed to clarify optimal dosing and refine patient selection.

The Bottom Line

• Your frontline judgment is exactly where this finding matters: NPs and PAs are not "backup" decision-makers here, but the clinicians most likely to identify who needs a credible next-step option.

• For peripheral neuropathic pain, bupropion appears to offer a modest, well-tolerated alternative when first-line treatments fail or cause side effects.

• If a patient is stuck between inadequate relief and poor tolerability, this study gives you evidence to support a thoughtful off-path choice.

Reference: The Effect of Bupropion in Peripheral Neuropathic Pain A Randomized, Double-Blind, Placebo-Controlled Study.